What's Happening?
Hanmi Pharm. Co., Ltd. has signed a licensing agreement with Eli Lilly and Company for the development, manufacturing, and commercialization of sonefpeglutide, a LAPSGLP-2 analog. This novel drug candidate utilizes Hanmi's LAPSCOVERY platform and is currently
in a global Phase 2 clinical trial for short bowel syndrome (SBS). The agreement grants Lilly exclusive rights to develop and commercialize sonefpeglutide worldwide, excluding Korea. Hanmi will receive an upfront payment of USD 75 million and may earn up to USD 1.185 billion in milestone payments, along with royalties post-launch.
Why It's Important?
This agreement represents a significant collaboration in the pharmaceutical industry, highlighting the potential of sonefpeglutide in addressing unmet medical needs. The partnership with Lilly, a major player in the industry, could accelerate the development and availability of this treatment. The financial terms of the deal reflect the high expectations for sonefpeglutide's success. This collaboration could also enhance Hanmi's reputation as an innovator in drug development, potentially leading to further partnerships and advancements in the field.
What's Next?
Lilly will explore additional clinical trials for sonefpeglutide, leveraging its nonclinical and clinical data. The ongoing Phase 2 trial in SBS will continue under Hanmi's oversight. Successful trials could lead to regulatory approvals and eventual commercialization, providing a new treatment option for patients with SBS and potentially other conditions. The collaboration may also inspire similar partnerships in the industry, fostering innovation and development of new therapies.
